Guided Therapeutics director awarded 110,000 options

GUIDED THERAPEUTICS INC director James Michael C received a grant of stock options covering 110,000 shares of common stock.

Rhea-AI Filing Summary

GUIDED THERAPEUTICS INC director James Michael C received a grant of stock options covering 110,000 shares of common stock. The options have an exercise price of $0.29 per share and expire on March 9, 2036.

According to the vesting terms, one-fourth of the options vested on March 10, 2026. The remaining options will vest in monthly installments starting on June 10, 2026, subject to his continued service, until full vesting on March 10, 2029. After this grant, he holds 110,000 stock options directly as reported in this filing.

Insider Trade Summary

Grant/Award: 110,000 shares

Grant/Award 1 txn

Insider JAMES MICHAEL C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	110,000	$0.00	$0.00

Holdings After Transaction: Stock Options — 110,000 contracts (Direct)

Footnotes (1)

1. F1. One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029.

Key Figures

Options granted: 110,000 options Exercise price: $0.29 per share Expiration date: March 9, 2036 +3 more

6 metrics

Options granted 110,000 options Stock options covering 110,000 shares of common stock

Exercise price $0.29 per share Conversion or exercise price of the stock options

Expiration date March 9, 2036 Option term end date for the granted stock options

Initial vesting 25% on March 10, 2026 One-fourth of the options vest on March 10, 2026

Final vesting date March 10, 2029 Award fully vested by March 10, 2029 with monthly vesting

Post-transaction holdings 110,000 options Total stock options directly held after the grant

Key Terms

Stock Options, Common Stock, vesting

3 terms

Stock Options financial

"security_title: Stock Options granted to the director"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Common Stock financial

"underlying_security_title: Common Stock linked to the options"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vesting financial

"shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Guided Therapeutics (GTHP) report for James Michael C?

Guided Therapeutics reported that director James Michael C received a grant of 110,000 stock options. The award is compensation, not an open-market purchase, and gives him the right to buy common shares at a fixed exercise price if vesting and other conditions are met.

What are the key terms of the 110,000 stock options granted at GTHP?

The grant covers 110,000 stock options with an exercise price of $0.29 per share and an expiration date of March 9, 2036. These options relate to Guided Therapeutics common stock and represent a long-dated equity incentive for the director’s future service.

How do the Guided Therapeutics (GTHP) director’s options vest over time?

One-fourth of the options vested on March 10, 2026. The remaining options vest in monthly installments beginning June 10, 2026, continuing until full vesting on March 10, 2029, provided the director remains in service on each scheduled vesting date.

Did the Guided Therapeutics (GTHP) director buy or sell shares in the market?

The filing shows a grant of stock options as compensation, not a market trade. No open-market buying or selling occurred; instead, the director received derivative rights to acquire common stock at $0.29 per share if and when options are exercised.

What is the director’s reported position after this GTHP option grant?

Following the transaction, the director is reported as directly holding 110,000 stock options. These options are tied to Guided Therapeutics common stock and become exercisable over the vesting schedule through March 10, 2029, subject to continued service conditions.

When do the newly granted Guided Therapeutics (GTHP) options expire?

The stock options granted to the director expire on March 9, 2036. After that date, any unexercised options become worthless, so the director must satisfy vesting conditions and exercise before expiration to convert them into Guided Therapeutics common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/07/2026 - 01:53 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JAMES MICHAEL C

(Last) (First) (Middle)

5835 PEACHTREE CORNERS

SUITE B

(Street)

PEACHTREE CORNERS GEORGIA 30092

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GUIDED THERAPEUTICS INC [ GTHP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$0.29	03/10/2026		A		110,000		(1)	03/09/2036	Common Stock	110,000	$0.00	110,000	D

Explanation of Responses:

1. One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029.

Remarks:

	/s/ Michael C James	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)